Mutant ARID1A: igniting cancer immunotherapy
- PMID: 39068111
- DOI: 10.1016/j.it.2024.07.003
Mutant ARID1A: igniting cancer immunotherapy
Abstract
Maxwell et al. show that ARID1A loss enhances antitumor immunity by triggering a type I IFN response through the cGAS-STING pathway, thereby promoting T cell infiltration and cytotoxicity. These findings highlight SWI/SNF inhibitors as a strategy to augment immunotherapy efficacy by potentially transforming non-responsive tumors into responders and advancing approaches to cancer treatment.
Copyright © 2024 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of interests E.T reports grants from AstraZeneca and consulting fees from Menarini. B.H.K. declares no competing interests.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
